Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
TRACON Pharmaceuticals, Inc. (DE:T051)
BERLIN:T051
RESEARCH TOOLSreports
TRACON Pharmaceuticals (T051) Stock Price & Analysis
1 Followers
T051 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.12 - €1.91
Previous Close€0.42
Volume11.74K
Average Volume (3M)9.27K
Market Cap
€18.11M
Enterprise Value€10.16M
Total Cash (Recent Filing)$8.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta0.64
Next Earnings
May 15, 2024EPS Estimate
-€0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,504,501
10 Day Avg. Volume0
30 Day Avg. Volume9,268
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-23.07
Price to Sales (P/S)27.01
Price to Cash Flow (P/CF)-8.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.84
Enterprise Value/Gross Profit0.84
Enterprise Value/Ebitda1.04
Forecast
1Y Price Target
€3.25Price Target Upside680.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
TRACON Pharmaceuticals News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
6.29% Other Institutional Investors
93.71% Public Companies and
Individual Investors
T051 FAQ
What was TRACON Pharmaceuticals, Inc.’s price range in the past 12 months?
TRACON Pharmaceuticals, Inc. lowest stock price was €0.12 and its highest was €1.91 in the past 12 months.
What is TRACON Pharmaceuticals, Inc.’s market cap?
Currently, no data Available
When is TRACON Pharmaceuticals, Inc.’s upcoming earnings report date?
TRACON Pharmaceuticals, Inc.’s upcoming earnings report date is May 15, 2024 which is in 26 days.
How were TRACON Pharmaceuticals, Inc.’s earnings last quarter?
TRACON Pharmaceuticals, Inc. released its earnings results on Mar 05, 2024. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of -€0.074 by €0.084.
Is TRACON Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts TRACON Pharmaceuticals, Inc.’s price is currently Undervalued.
Does TRACON Pharmaceuticals, Inc. pay dividends?
TRACON Pharmaceuticals, Inc. does not currently pay dividends.
What is TRACON Pharmaceuticals, Inc.’s EPS estimate?
TRACON Pharmaceuticals, Inc.’s EPS estimate is -€0.06.
How many shares outstanding does TRACON Pharmaceuticals, Inc. have?
Currently, no data Available
What happened to TRACON Pharmaceuticals, Inc.’s price movement after its last earnings report?
TRACON Pharmaceuticals, Inc. reported an EPS of €0.009 in its last earnings report, beating expectations of -€0.074. Following the earnings report the stock price went up 5.882%.
Which hedge fund is a major shareholder of TRACON Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in DE:T051
---
TRACON Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€3.25 (680.73% Upside)
€3.25 (680.73% Upside)
Blogger Sentiment
Bearish
DE:T051 Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-76.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-48.10%
Trailing 12-Months
Company Description
TRACON Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
---
T051 Earnings Call
Q4 2024
0:00 / 0:00
---
T051 Stock 12 Months Forecast
Average Price Target
€3.25
▲(680.73% Upside)
Technical Analysis
Achieve Life Sciences
―
Karyopharm Therapeutics
―
Kura Oncology
―
TRACON Pharmaceuticals
―
Onconova Therapeutics
―
Best Analysts Covering T051
1 Year
1 Year Success Rate
3/22 ratings generated profit
1 Year Average Return
-39.55%
reiterated a buy rating last month
Copying Edward White's trades and holding each position for 1 Year would result in 13.64% of your transactions generating a profit, with an average return of -39.55% per trade.
---